TrialAmerican journal of clinical dermatology2025

Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks.

Alan D Irvine et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.